Broken String Biosciences

Broken String Biosciences appoints Steve Becker as Chief Commercial Officer

Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer....

Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research

Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis 07 May 2024 -- Cambridge and London, UK -- Broken String Biosciences, a genomics company driving development of the next generation of more precise, safe and effective cell and gene therapies (CGTs),...

Broken String Biosciences appoints Gavin Burns as Vice President of Quality and Operations

Experienced quality assurance professional joins team to support ongoing strategic growth plans as the company expands access and capabilities of INDUCE-seq DNA break mapping platform Expansion to leadership team follows recent appointments of Vincent Smith as chief technology officer and Jessica Rich as vice president of Business Development 22 November 2023 -- Cambridge, UK --...

Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing

Research published in Molecular Cell used INDUCE-seq to identify DNA topology as an important regulator of CRISPR targeting specificity Peer-reviewed data demonstrates the sensitivity of INDUCE-seq DNA break mapping platform, in identifying topology-related off-target events across the genome in cells 18 October 2023 -- Cambridge, UK -- Broken String Biosciences, a genomics company building a...

Broken String Biosciences strengthens senior leadership team to accelerate product development and commercialisation

Appointment of Vincent Smith PhD, as chief technology officer and Jessica Rich as VP of Business Development Follows Broken String’s successful $15m Series A fundraising round in September 2023 Will support development and commercialisation strategy for INDUCE-seq DNA break-mapping platform 2 October 2023 -- Cambridge, UK -- Broken String Biosciences, a genomics company building a...

Broken String Biosciences Closes $15m Series A Funding Round

Funds to support further development and commercialisation of the company’s INDUCE-seq DNA break mapping technology Platform technology provides in situ off-target measurement in clinically relevant cells to accelerate the progression of cell and gene therapy programmes New investors include Illumina Ventures, Mérieux Equity Partners and HERAN Partners 18 September 2023 -- Cambridge, UK -- Broken...
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Genome Campus Hinxton Cambridge, CB10 1DR

+44(0)1223 786 071